Prescription opioid analgesic use in France: Trends and impact on morbidity-mortality

Eur J Pain. 2019 Jan;23(1):124-134. doi: 10.1002/ejp.1291. Epub 2018 Aug 20.

Abstract

Background: While data from USA and Canada demonstrate an opioid overdose epidemic, very little nation-wide European studies have been published on this topical subject.

Methods: Using a nationally representative sample of the French Claims database (>700,000 patients), the exhaustive nationwide hospital discharge database, and national mortality registry, all patients dispensed at least one prescription opioid (PO) in 2004-2017 were identified, to describe trends in PO analgesic use, shopping behaviour, opioid-related hospitalizations and deaths. Annual prevalence of PO use and shopping behaviour (≥1 day of overlapping prescriptions from ≥2 prescribers, dispensed by ≥3 pharmacies) was estimated.

Results: In 2004-2017, the annual prevalence of weak opioid use codeine, tramadol and opium rose by 150%, 123%, and 244%, respectively (p < 0.05). Strong opioid use increased from 0.54% to 1.1% (+104%, p < 0.05), significantly for oxycodone (+1950%). Strong opioid use in chronic noncancer pain rose by 88% (p < 0.05) and 1180% for oxycodone. Opioid shopping increased from 0.50% to 0.67% (+34%, p < 0.05), associated with higher mortality risk HR = 2.8 [95% confidence interval (CI): 1.2-6.4]. Opioid-related hospitalizations increased from 15 to 40 per 1,000,000 population (+167%, 2000-2017), and opioid-related deaths from 1.3 to 3.2 per 1,000,000 population (+146%, 2000-2015).

Conclusions: This study provided a first European approach to a nationwide estimation with complete access to several national registries. In 2004-2017 in France, PO use excluding dextropropoxyphene more than doubled. The increase in oxycodone and fentanyl use, and nontrivial increasing trend in opioid-related morbidity-mortality should prompt authorities to closely monitor PO consumption in order to prevent alarming increases in opioid-related morbidity-mortality.

Significance: In 2004-2017, prescription opioid use in France at least doubled and oxycodone use increased particularly, associated with a nontrivial increase in opioid-related morbidity-mortality. Although giving no indication for an 'opioid epidemic,' these findings call for proper monitoring of opioid use.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Analgesics, Opioid / therapeutic use*
  • Chronic Pain / drug therapy*
  • Codeine / therapeutic use
  • Databases, Factual
  • Dextropropoxyphene / therapeutic use
  • Female
  • Fentanyl / therapeutic use
  • France / epidemiology
  • Humans
  • Male
  • Middle Aged
  • Mortality*
  • Opioid-Related Disorders / epidemiology*
  • Opium / therapeutic use
  • Oxycodone / therapeutic use
  • Prevalence
  • Proportional Hazards Models
  • Tramadol / therapeutic use

Substances

  • Analgesics, Opioid
  • Tramadol
  • Opium
  • Oxycodone
  • Dextropropoxyphene
  • Fentanyl
  • Codeine